The following management's discussion and analysis ("MD&A") should be read in conjunction with financial statements of Taihe Group, Inc. formerly NuOncology Labs, Inc. (the "Company") for the three and nine months ended September 30, 20221 and 2021, and the notes thereto.

Safe Harbor for Forward-Looking Statements

Certain statements included in this MD&A constitute forward-looking statements, including those identified by the expressions anticipate, believe, plan, estimate, expect, intend, and similar expressions to the extent they relate to Taihe Group, Inc. formerly NuOncology Labs, Inc. (the "Company") or its management. These forward-looking statements are not facts, promises, or guarantees; rather, they reflect current expectations regarding future results or events. These forward-looking statements are subject to risks and uncertainties that could cause actual results, activities, performance, or events to differ materially from current expectations. These include risks related to revenue growth, operating results, industry, products, and litigation, as well as the matters discussed in Taihe Group, Inc. formerly NuOncology Labs, Inc.'s MD&A. Readers should not place undue reliance on any such forward-looking statements. Taihe Group, Inc. formerly NuOncology Labs, Inc. disclaims any obligation to publicly update or to revise any such statements to reflect any change in the Company's expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.





Overview

Taihe Group, Inc. formerly NuOncology Labs, Inc. is a blank check company and has no operations. Our business plan includes acquisitions of operating companies. The focus of the Company's future business involves finance, trade, culture, tourism, real estate, new energy, health care, etc. between China and Indonesia under the "One Belt and One Road" initiatives in Indonesia. The Company operates and intends to further obtain a diversified portfolio of subsidiary companies. With a variety of assets, products, and ancillary offerings in a variety of industries, management believes the Company's business model is positioned to capitalize on, and adapt to, changing market conditions. As of this filing, we have not raised any capital and our business is not yet operational, and the Company is focused on raising capital for its business plan.

On March 10, 2022 (the "Effective Date"), Nuoncology Labs, Inc. filed Articles of Amendment (the "Amendment") with the Florida Secretary of State amending the Company's Amended Articles of Incorporation to effect:





       1)  a corporate name changed from Nuoncology Labs, Inc. to Taihe Group,
           Inc.; and
       2)  a one-for-thirty thousand (1:30,000) reverse stock split of the
           Company's class of common stock with all other aspects to remain
           unchanged




Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes included in this report

Three Months Ended September 30, 2022 and 2021





Revenue

For the three months ended September 30, 2022 and 2021, the Company had not generated any revenues.





Operating Expenses

Operating expenses for the three months ended September 30, 2022 were $4,638 compared to $0 for the three months ended September 30, 2021. Operating expenses increased in 2022 due to other professional fee and other general and administrative fees incurred for this period.









  12

For the three months ended September 30, 2022, professional fees were $3,438, an increase of $3,438, as compared to $0 for the three months ended of September 30, 2021. The increase is related to accounting and audit fees, and SEC filing fees between the two periods.





Other Income and Expenses

For the three and three months ended September 30, 2022 and 2022, the Company did not have any other income or expenses.





Net Income (Loss)

For the three months ended September 30, 2022, the Company had a net loss of $4,638 compared to the three months ended September 30, 2021 of a net loss of $0. The net loss resulted from increase of operating expenses

Nine Months Ended September 30, 2022 and 2021





Revenue

For the six months ended September 30, 2022 and 2021, the Company had not generated any revenues.





Operating Expenses

Operating expenses for the nine months ended September 30, 2022 were $31,069 compared to $0 for the nine months ended September 30, 2021. Operating expenses increased in 2022 due to other professional fee and other general and administrative fees incurred for this period.

For the nine months ended September 30, 2022, professional fees were $21,419, an increase of $21,419, as compared to $0 for the nine months ended of September 30, 2021. The increase is related to accounting and audit fees, and SEC filing fees between the two periods.





Other Income and Expenses

For the nine months ended September 30, 2022 and 2022, the Company did not have any other income or expenses.





Net Income (Loss)

For the nine months ended September 30, 2022, the Company had a net loss of $31,069 compared to the six months ended September 30, 2021 of a net loss of $0. The net loss resulted from increase of operating expenses

Liquidity and Capital Resources

As of September 30, 2022, we had no cash and a working capital deficit of $31,069.

The Company has not generated any revenues from operations, and may be unable to fund on-going activities. We cannot guarantee that we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays in developing our own hardware and software, and the possibility of new regulations that will make our company difficult or impossible to operate.

If we are unable to meet our needs for cash from either our operations, or possible alternative sources, then we may be unable to continue, develop, or expand our operations.









  13

If we are unable to complete any phase of our development program or fail to raise additional capital to maintain our operations in the future, we may be unable to carry out our full business plan or we may be forced to cease operations.

The Company's related party will continue to advance the necessary capital to pay the expenses of the Company and there are no formal financing agreements in place. The outstanding amount due to related parties was $29,298 and $0 as of September 30, 2022 and December 31, 2021.





Operating Activities

Net cash used in operating activities was $20,331 for the nine months ended September 30, 2022 as compared to $0 for the same period in 2021.

For nine months ended September 30, 2022 net operating loss was $31,069 as compared to $0 for the nine months ended September 30, 2021. Accounts payable and accrued expenses increased by $10,171 as compared to $0 for the nine months ended September 30, 2021. The increase in accrued expenses is related to other professional fees.





Investing Activities

No investing activities occurred during the nine months ended September 30, 2022 and 2021.





Financing Activities

Net cash provided by financing activities was $20,898 for the nine months ended September 30, 2022 as compared to $0 for the same period in 2021.

During the nine months ended September 30, 2022, the Company received advances of $20,898 from a related party for working capital purposes.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements with any party.





Critical Accounting Policies

Our discussion and analysis of results of operations and financial condition are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those related to provisions for uncollectible accounts receivable, inventories, valuation of intangible assets and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The accounting policies that we follow are set forth in Note 2 to our financial statements as included in the SEC report filed. These accounting policies conform to accounting principles generally accepted in the United States and have been consistently applied in the preparation of the financial statements.









  14

© Edgar Online, source Glimpses